-- 根據韓國交易所週三發布的公告顯示，Celltrion（KRX：068270）公佈第一季歸屬於股東的淨利潤為3,461億韓元，較去年同期的1,087億韓元成長219%。 這家韓國生物製藥公司的銷售額年增36%，從8,419億韓元增至1.144兆韓元。 Celltrion股價在收盤時下跌近2%。
Related Articles
Equities
Ta'Ziz, Alpha Dhabi Holding to Invest $10 Billion for Industrial Chemicals Production in UAE
Alpha Dhabi Holding (ADX:ALPHADHABI) and Ta'Ziz, a joint venture between ADQ and Abu Dhabi National Oil Co., d/b/a Adnoc, signed a collaboration agreement to strengthen the United Arab Emirates' domestic production of new industrial chemicals.The partnership will invest $10 billion in the production of up to 14 new chemicals, with a targeted additional chemical capacity of 2.2 million tonnes per annum at Ta'Ziz's facility in Al Ruwais Industrial City, Abu Dhabi, according to a Wednesday release.The new chemicals, which are used across a wide range of sectors, could substitute key products that are currently imported into the UAE and help improve its local supply chain resilience.
$ADX:ALPHADHABI
Equities
Natural Resource Partners Q1 Earnings, Revenue Decrease
Natural Resource Partners (NRP) reported Q1 earnings Wednesday of $1.44 per diluted common unit, down from $2.97 a year earlier.Revenue for the quarter ended March 31 was $39.4 million, down from $60.5 million a year earlier.The company also set a cash distribution of $0.75 per common unit, payable May 26 to unitholders on May 19.
$NRP
Research
Research Alert: Insulet Reports Strong Q1 Led By Omnipod Growth And International Expansion
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Insulet delivered solid Q1 2026 results with revenue of $761.7M (+33.9% Y/Y) exceeding guidance and beating consensus by $32M, while adjusted EPS of $1.42 (+39.2%) surpassed expectations by $0.23. Omnipod revenue grew 36.9% to $758.4M, led by 28.3% U.S. growth and 59.4% international expansion, with adjusted operating margin expanding 110 bps to 17.5% despite gross margin pressure. We view the Type 2 diabetes AID progress positively, with encouraging EVOLUTION 2 trial data showing 68% time in range and first participant enrolled in the pivotal EVOLVE study for 2027 510(k) filing. Management raised its 2026 revenue guidance to 21%-23% Y/Y constant currency growth (from 20%-22% Y/Y previously), while maintaining ~100 bps adjusted operating margin expansion and over 25% adjusted EPS growth outlook. We believe the combination of accelerating international momentum, Type 2 diabetes opportunity, and strong cash generation positions Insulet well for continued growth.
$PODD